



2025 Healthtech Apex 20

20 Portfolio Companies We Are Proud to Spotlight

[Learn How You Can Invest in Companies Like These](#)



We are pleased to announce our **2025 Healthtech Apex 20**.

We are proud to unveil our 2025 Healthtech Apex 20 — a curated collection of standout companies from Alumni Ventures' portfolio of healthcare investments. This year's selections reflect powerful trends reshaping the industry:

- AI is taking center stage, powering breakthroughs across diagnostics, drug discovery, care delivery, and operational efficiency.
- Care is becoming more personalized and proactive, with tools that meet patients where they are — whether at home, online, or in underserved systems.
- Healthcare infrastructure is undergoing a tech-driven overhaul, from pharmacy benefits and payments to supply chains and emergency response.
- Aging and chronic conditions remain top priorities, with innovations focused on metabolic health, neurodegenerative diseases, and aging-in-place services.

These ventures are not only transforming care for millions but also generating strong commercial traction, backed by leading VC firms and strategic healthcare partners.

OURA

Smart Ring for Metabolic & Sleep Health

[Watch Our Deal Breakdown](#)

- Tracks sleep, activity, stress levels, glucose, and more
- Offers AI-generated health insights via mobile app
- Over one million users; partnering with retailers like Target and Amazon
- Co-investors: Forerunner Ventures, Gradient Ventures, Square, Marc Benioff

Pendulum

Microbiome-Based Therapeutics

- Develops patented probiotics and therapies to restore gut health and treat Type 2 diabetes and obesity
- Created Glucose Control, the only medical probiotic on the market clinically shown to improve A1C in Type 2 diabetes
- Posted 25% QoQ growth for four consecutive quarters; nearly tripled YoY revenue
- Co-investors: Sequoia Capital, Khosla Ventures, True Ventures

honor

AI-Enabled Senior Home Care

- Partners with local agencies and caregivers to provide high-quality, nonmedical home care for the geriatric market
- Serves the growing senior population utilizing AI-powered scheduling and support
- A16z's Marc Andreessen sits on the board; positioned as a market leader in aging-in-place care
- Co-investors: Andreessen Horowitz, 8VC, Thrive Capital



ezra

Full-Body AI-Driven Cancer Screening

- Uses FDA-cleared AI to deliver fast, accurate, and affordable MRI-based cancer screening
- Advancing AI for cancer detection with potential to outperform radiologists in imaging accuracy
- Acquired by Function Health, a longevity startup with lab testing capabilities
- Co-investors: FirstMark, Accomplice

Forta

Parent-Led Pediatric Mental Health Care

- Improves youth mental health with a parent-led model that empowers families through tools, resources, and support
- Doubled revenue in its second year, proving model scalability and clinical demand
- Plans to expand beyond autism therapy to memory care and other chronic conditions
- Co-investors: Insight Partners

Precision

Minimally Invasive Brain-Computer Interfaces

- Founded by a Neuralink co-founder, develops AI-driven, minimally invasive brain-computer interfaces for neurological disorders
- Restores function for people with severe neurological conditions like stroke, spinal cord injury, TBI, and ALS
- First fully wireless BCI company to receive FDA approval for commercial use
- Co-investors: B Capital, Draper Associates

Clarium

AI Supply Chain Automation for Health Systems

- Platform unifies hospital and supplier data to automate and optimize healthcare supply chains
- Working with leading health systems to drive millions in savings via AI-driven planning
- Raised \$10.5M to scale Astra OS, a healthcare platform that automates and optimizes provider supply chains
- Co-investors: General Catalyst, Kaiser Permanente Ventures, Texas Medical Center Venture Fund

The Helper Bees®

Aging-in-Place Non-Medical Care Platform

- Helps insurers support aging in place by connecting older adults with nonmedical services like meals, transportation, and home care
- Vetted provider network is integrated with long-term care and Medicare Advantage plans to close the care gap
- Launched a unified payment card, with access to 60,000+ retail locations, streamlining benefit delivery to homes
- Co-investors: Trust Ventures, Centana Growth Partners, Silverton Partners, Northwestern Mutual



Cambrian

**Distributed Drug Development
for Longevity**

- Uses a distributed drug discovery model to target age-related diseases through a diversified portfolio of 14 assets
- Approach reduces development risk, with successes like Sensei Bio's \$600M IPO
- Lead candidate ATX-30 shows promise in reducing muscle loss, a GLP-1 side effect
- Co-investors: Anthos Capital, Apeiron Investment Group, Future Ventures, Moore Capital



Transparent Pharmacy Benefit Manager

- Offers a transparent, tech-driven alternative to traditional PBMs, eliminating hidden fees and markups
- Platform streamlines drug benefit management for employers and health plans, reducing overall healthcare costs
- Achieved 5x revenue growth; platform now adopted by major employer health plans
- Co-investors: General Catalyst, Mubadala Capital, Edison Partners



Digital Twin Platform for Clinical Trials

- Accelerates clinical trials with synthetic control groups using digital twins — virtual representations of patients that can simulate treatment responses and predict clinical outcomes
- Supports real-time trial planning with predictive patient modeling tools
- Partnered with Trace Neuroscience on ALS trial design
- Co-investors: DCVC, 8VC, Mubadala Capital



**AI-Enhanced Emergency
Response Network**

- Enhances emergency response by delivering real-time, data-driven insights to 911 centers and first responders
- Integrates data from smartphones, wearables, and IoT sensors to provide location, medical history, and environmental context
- Harmony AI platform enables telecommunicators to automate 911 dispatch via voice
- Co-investors: Insight Partners, Blackrock, Playground Global



**AI-Driven Drug Discovery
for Neurology**

- Uses AI and human genomics to accelerate drug discovery for neurodegenerative diseases
- Identifies novel drug targets for conditions like Alzheimer's, Parkinson's, and ALS
- Secured major pharma partnerships and ~\$67M in contracts with Eli Lilly and Alexion
- Backed by strong funding, IP, and a growing pipeline of preclinical and clinical drug candidates
- Co-investors: AstraZeneca, Blackrock, Draper Associates



**Localized Immunotherapy
Delivery Platform**

- Revolutionizing cancer treatment with a drug delivery platform that precisely targets solid tumors for higher efficacy and fewer side effects
- Demonstrated 70% tumor reduction in preclinical trials
- Backed by leading oncology centers and pioneering intra-surgical immunotherapy
- Co-investors: Khosla Ventures, 8VC, DHVC, Bioluminescence Ventures



AI Claims Review for Payers and Labs

- Uses AI to streamline claims review and eliminate inefficiencies in the \$200B+ healthcare payment industry
- Rapid revenue scale with proven results at Quest, Labcorp
- Partnered with Availity, "the nation's largest real-time health information network," giving Anomaly access to Availity's massive provider network
- Co-investors: RRE Ventures, Madrona, Sound Ventures, Link Ventures



**Microrobots for Precision
Brain Therapy**

- Developer of a rice-sized robot that navigates the central nervous system to deliver drugs, perform microsurgery, or collect biopsy samples
- Collaborating with Mayo Clinic and multiple U.S. centers
- Preparing for first human trials using magnetically guided micro-robots for tumor access
- Co-investors: Gates Ventures, Khosla Ventures, Mayo Clinic, Altitude Life Sciences



**Nationwide Hybrid Mental
Health Platform**

- Offers AI-powered mental health care, matching clients with providers and delivering personalized support through its app
- Expanded virtual mental health services to all 50 states, adding New York and Michigan in 2025
- Grew its contractor provider network to 12,000 practitioners
- Co-investors: General Catalyst, Drive Capital, Premji Invest



Physics-Based AI for Drug Discovery

- Uses physics-based AI to solve complex drug design challenges and accelerate therapeutic discovery
- Platform has outperformed Google's AlphaFold in predictive capabilities
- In May 2025, launched Enchant v2, which dramatically boosts molecular prediction accuracy with 10x model scale and new AI innovations
- Co-investors: Sequoia Capital, NVIDIA, Abingworth



Fusion-Based Medical Isotope Manufacturing

- Supplies Lu-177 and Mo-99 for imaging and therapy
- Positioned to become largest global supplier of critical medical isotopes
- Acquired SPECT division from Lantheus; building isotope mega-facility
- Co-investors: Fidelity Growth Fund, Oaktree Capital, Deerfield Capital Management



AI Voice Biomarkers for Emotional Health

- Uses AI to detect mental health biomarkers through everyday conversation, helping identify and manage conditions early
- Adopted by UnitedHealth, Highmark, and HCA
- Developed Sage, an AI voice agent powered by the Empathy Engine, to support clinicians and improve care access 24/7.
- Co-investors: Khosla Ventures, Greycroft

NOTE: Portfolio company investments shown for illustrative purposes only. No representation is intended that the outcomes shown or discussed are representative of the outcomes experienced by any AV fund or investor. Co-investors listed are for illustration purposes only. The example investments are not available for future investors, except potentially in the case of follow-on investments. These co-investors are some that AV has historically co-invested with and is not a predictor of future co-investors for any given portfolio company. There is no guarantee of who will be the co-investors in any given investment, and the identity of a co-investor is not necessarily predictive of investment outcomes.

Important Disclosure Information: The manager of the AV Funds is Alumni Ventures (AV), a venture capital firm. AV and the funds are not affiliated with or endorsed by any college or university. These materials are provided for informational purposes only. Offers of securities are made only to accredited investors pursuant to each fund's offering documents, which describe among other things the risks and fees associated with the Fund that should be considered before investing. The funds are long-term investments that involve a substantial risk of loss, including the loss of all capital invested. Past performance is not indicative of future results. Opportunities to invest in any security (of a Fund, of AV or in a syndication offering) is not a guarantee

that you will be able to invest and are subject to all terms of the specific offering. Diversification cannot ensure a profit or protect against loss in a declining market. It is a strategy used to help mitigate risk.

Any investment performance or outcomes discussed with you is provided for illustrative purposes only. Except where expressly noted, no representation is intended that any investment outcome shown or discussed is, or would be, representative of results obtained by any fund or investor associated with AV. F22-X0740-250611.01